Stay updated on Selitrectinib Safety Study in Children and Adults Clinical Trial
Sign up to get notified when there's something new on the Selitrectinib Safety Study in Children and Adults Clinical Trial page.

Latest updates to the Selitrectinib Safety Study in Children and Adults Clinical Trial page
- Check5 days agoChange DetectedA new revision label 'Revision: v3.6.3' was added and the previous label 'Revision: v3.6.2' was removed, updating the page's version metadata in the history.SummaryDifference0.0%

- Check13 days agoChange DetectedThe revision history now shows a new site revision (v3.6.2) replacing the previous version (v3.6.0). This reflects an update to the page's versioning information in the history.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe history now shows the study is no longer recruiting participants, indicating a closed recruitment status. The history also adds a new revision tag (Revision: v3.6.0) and removes the previous tag (Revision: v3.5.5) from the record.SummaryDifference0.2%

- Check34 days agoChange DetectedRevision: v3.5.5 is now listed as the latest version, replacing Revision: v3.5.4 in the study record history. This indicates a software release update to the ClinicalTrials.gov record page; no study data or user-facing content appears to be modified.SummaryDifference0.0%

- Check55 days agoChange DetectedA new revision entry, v3.5.4, was added to the study record history, replacing the prior v3.5.3 entry. This indicates that the record has been updated.SummaryDifference0.0%

- Check76 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a change to the site’s display software rather than any study information.SummaryDifference0.0%

Stay in the know with updates to Selitrectinib Safety Study in Children and Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selitrectinib Safety Study in Children and Adults Clinical Trial page.